All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside

Cencora (COR) gets its prior buy rating from 2025 reaffirmed, driven by several strong fundamentals, despite a recent price retreat. The healthcare distributor has a global brand footprint, a key role in serving specific clinical needs, and profitability, despite thin margins. The dividend case is compelling, with proven 10 year growth across many market cycles, and a low payout ratio.